Blepharospasm Patient Survey for Patients With Blepharospasm

Merz Pharmaceuticals

Status: Completed

Conditions: Blepharospasm

Treatments: Other: No intervention- only one time survey

Study type: Observational

Funder types: Industry

Identifiers

NCT01686061

MUS6020100920

Details and patient eligibility

About

The purpose of this survey is to collect detailed information on patients treated for blepharospasm with incobotulinumtoxinA, abobotulinumtoxinA and onabotulinumtoxinA, including how often they are treated with botulinum toxin, how long their treatment lasts, how satisfied they are with their treatment, and if there is any improvement in their symptoms with the treatment.

Full description

This study is open to males and females > 18 years and < 81 years with a clinical diagnosis of blepharospasm.

Enrollment: 124 patients

Sex: All

Ages: 18 to 81 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Male or female subject aged > 18 years and < 81 years
• Documented clinical diagnosis of blepharospasm
• Currently receiving incobotulinumtoxinA, abobotulinumtoxinA or onabotulinumtoxinA

Exclusion criteria

• Previous treatment with rimabotulinumtoxinB in the last 2 treatment cycles

Trial design

124 participants in 1 patient group

Blepharospasm Survey Group

Treatment:

Other: No intervention- only one time survey